Ursodiol

CHEMBL1551 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

392.6 g/mol

LogP

4.9

Phase

4

Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurring hydrophilic bile acid that reduces cholesterol saturation in bile by decreasing hepatic cholesterol secretion and absorption, and also exerts cytoprotective and anti-inflammatory effects on hepatocytes and cholangiocytes. It is approved for dissolving cholesterol gallstones, treating primary biliary cholangitis (PBC), and preventing gallstone formation after bariatric surgery, and is investigated in colorectal cancer prevention and other liver conditions. Its hepatoprotective mechanism involves displacement of toxic hydrophobic bile acids.

Molecular Weight

392.6000 g/mol

LogP

4.90

TPSA

77.80 Å²

Lipinski RO5

Pass

Therapeutic Areas

Breast Cancer Colorectal Cancer Gastroesophageal Reflux Disease Heart Failure Hepatitis C Hyperlipidemia Hypertension Leukemia Non-Alcoholic Fatty Liver Disease Obesity Parkinson's Disease Rheumatoid Arthritis Type 2 Diabetes

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1

Molecular Formula

C24H40O4

HBD / HBA

3 / 4

Rotatable Bonds

4

Heavy Atoms

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurring hydrophilic bile acid that reduces cholesterol saturation in bile by decreasing hepatic cholesterol secretion and absorption, and also exerts cytoprotective and anti-inflammatory effects on hepatocytes and cholangiocytes. It is approved for dissolving cholesterol gallstones, treating primary biliary cholangitis (PBC), and preventing gallstone formation after bariatric surgery, and is investigated in colorectal cancer prevention and other liver conditions. Its hepatoprotective mechanism involves displacement of toxic hydrophobic bile acids.

Yes, Ursodiol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1551. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 31401. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Looking for patient-friendly information?

Ursodiol on PillFYI

Structure

Quick Data

Formula: C24H40O4
Synonyms: 5

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.